Company Research Report: Vida Ventures, LLC
Company Overview
- Name: Vida Ventures, LLC
- Mission: Vida Ventures aims to bring science to life and advance transformative biomedical innovations that have the potential to make a meaningful difference in patients' lives.
- Founded: 2017
- Founders: A group of scientists, physicians, entrepreneurs, and investors. Known founders include David Bonderman who has been mentioned as a significant founding influence.
- Key People:
- Arie Belldegrun
- Helen S. Kim
- Rajul Jain
- Jean-Philippe Kouakou-Zebouah
- Chris Weyrer
- Jill Goldstein
- Mark Springel
- Alex Loftis
- David Chang
- Norbert Bischofberger
- Joshua Kazam
- David Tanen
- Christine Cassiano
- Kate Bechtold
- Alex Shen
- Victoria Stephens
- Stephanie Ott
- Several other team members spanning various functional areas.
- Headquarters: Boston, Massachusetts; also has a presence in Los Angeles, California.
- Number of Employees: 11-50 employees
- Revenue: No information is available
- Known For: Vida Ventures is recognized as a next-generation life sciences investment firm, managing approximately $1.8 billion and being deeply involved in the biotechnology sector.
Products
Vida Ventures, being an investment firm, does not offer products in the conventional sense but supports and funds biotechnology companies developing innovative therapies. Below are primary segments influenced by their investments:
- RIPTAC™ Cancer Therapies: Through their portfolio company, Halda Therapeutics.
- Description: Developing therapies for major solid tumors.
- Key Features: Focus on improving outcomes for cancer patients by overcoming drug resistance.
Recent Developments
- Strategic Collaborations and Partnerships:
- Aktis Oncology's partnership with Lily to develop novel anticancer radiopharmaceuticals.
- Financing and Investment Activities:
- Halda Therapeutics secured $126 million financing.
- Third Arc Bio launched with a $165 million Series A financing focusing on biologics for solid tumors and inflammatory diseases.
- Scorpion Therapeutics raised $150 million in Series C financing, with further news of being acquired by Eli Lilly up to $2.5 billion.
- Vigil Neuroscience secured a $40 million strategic investment from Sanofi.
- Tectonic Therapeutic completed a merger with AVROBIO and secured $130.7 million in private placement funding.
- Leadership Changes:
- Halda Therapeutics appointed Chris Schade as President and CEO to advance cancer therapies.
- Precision Medicine Group appointed Margaret Keegan as CEO to accelerate global access to novel therapies.
- Clinical Milestones:
- ReCode Therapeutics dosed the first patient in a Phase 1b trial of RCT2100, an investigational inhaled mRNA therapy for cystic fibrosis.
- Significant Loss:
- The passing of David Bonderman, one of the friends and founders, impacting the foundational aspect of the company's culture and legacy.
This report provides a detailed overview of Vida Ventures, exploring their mission, strategic goals, and recent developments in the life sciences domain. The venture capital firm continues to make significant strides in transforming biomedical innovations into therapies that promise meaningful changes in patient care.
